Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GENO.STthis companyGenovis AB	SEK 21.00	59.03×	5.15×	10.84×	34.56×	-59.9%	21.3%	21.3%	18.2%	8.7%	6.8%	2.2%	0.52×	-0.59×	7.29×	7.36×	0.0%	4	8.04	3	B-
BICO.STBICO Group AB (publ)	SEK 23.75	-1.36×	0.85×	0.99×	-48.97×	-130.1%	38.9%	-16.8%	-72.7%	-62.3%	-7.9%	3.7%	0.86×	-6.38×	-0.78×	1.27×	0.0%	6	-2.84	3	B-
CANTA.STCantargia AB (publ)	SEK 1.55	7.08×	3.91×	3.28×	4.91×	1047.8%	99.0%	48.7%	46.4%	55.3%	57.9%	14.4%	0×	-1.83×	11.37×	9.8×	0.0%	5	3.27	4	A
DMYD-B.STDiamyd Medical AB (publ)	SEK 0.98	-0.58×	0.61×	310.44×	0.62×	98.3%	-478.8%	-54562.9%	-53583.4%	-104.9%	-78.6%	-132.6%	0×	1.21×	-73.88×	9.08×	0.0%	3	-0.68	2	B-
ITECH.STI-Tech AB	SEK 62.60	18.78×	3.58×	3.71×	9.05×	172.1%	28.2%	26.5%	19.7%	19.0%	20.3%	10.3%	0×	-2.82×	47.44×	9.11×	3.3%	5	14.46	4	A-
ONCO.STOncopeptides AB (publ)	SEK 1.82	-4.37×	-18.53×	15.35×	-5.24×	-767.7%	83.0%	-317.6%	-350.9%	423.8%	-230.4%	-20.4%	-2.37×	-0.26×	-15.63×	2.63×	0.0%	3	0.46	1	D+
Peer median	—	-0.58×	0.85×	3.71×	0.62×	98.3%	38.9%	-16.8%	-72.7%	19.0%	-7.9%	3.7%	0×	-1.83×	-0.78×	9.08×	0.0%	5	0.46	3	—